On September 20th, the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) will jointly host a public meeting titled "Advancing the End of Tobacco Addiction: FDA and NIH Priorities" on October 21st from 9:00 am to 4:30 pm. The purpose of this meeting is to promote innovation in smoking cessation products to assist adults and adolescents in quitting smoking.
The conference will feature multiple speeches and panel discussions on smoking cessation. Topics of discussion will include perspectives from clinical and community settings, promising areas for development targets, and future regulatory pathways. Additionally, the conference will provide an opportunity for open commentary, allowing the public to voice opinions on various related topics.
This conference is open to the public free of charge. It is worth noting that in-person participation requires registration by October 15, 2024, and virtual attendance can be registered by 9 a.m. (EDT) on the day of the conference. If you wish to speak during the public comment session in person, registration must be completed by 5 p.m. (EDT) on October 1st.
Written reviews must be submitted by November 21, 2024 through the Regulations.gov public docket archive [Docket No. FDA-2024-N-4085].
The U.S. Department of Health and Human Services (HHS) support and accelerate smoking cessation framework clearly outlines the goal of promoting continued and innovative research on smoking cessation. The agency stated that the joint FDA and NIH meeting in October was specifically to support these efforts, aimed at driving a collective effort across society to improve the nation's health.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
